Pro 2013-001 (Announcement on Resolution of 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2013-001
Zhejiang Jianfeng Group Co., Ltd.
Resolution Announcement of the 8th Meeting of the 8th Board of Directors
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
On December 20, 2012, Zhejiang Jianfeng Group Co., Ltd. issued a notice to convene the eighth meeting of the eighth board of directors by fax, e-mail, telephone, and personal delivery. On December 31, 2012, the meeting was held as scheduled by means of communication. The company currently has nine directors, and nine directors participating in the voting , comply with the provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting passed the following resolutions:
1. the "Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds"
According to the "the People's Republic of China Company Law", "the People's Republic of China Securities Law", "Corporate Bond Issuance Pilot Measures" And other relevant regulations, in accordance with the conditions for listed companies to issue corporate bonds, the company meets the conditions and requirements stipulated by the current policies and laws and regulations for issuing corporate bonds, eligible to issue corporate bonds.
Voting result :__9__ votes yes, __0__ votes no, __0__ votes abstaining.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation and voting.
2. "Proposal on Issuing Corporate Bonds";
Meeting deliberated and approved item by item: 1 , issuance scale ; 2 , allotment arrangement to the original shareholders of the company ; 3 , bond term ; 4 , bond interest rate and determination method ; 5 , issuance method ; 6 , issuance object ; 7 , guarantee arrangement; 8 , use of raised funds ; 9 , listing of issued bonds ; 10 , Effective date of resolution . For details, please refer to the "Announcement on the Issuance of Corporate Bonds" published on the same day. At the meeting of
, there were 82 votes , results were all :__9__ votes in favor, __0__ votes against, and __0__ votes abstained.
The above proposals still need to be submitted to the general meeting of shareholders for deliberation and submitted to the China Securities Regulatory Commission for approval.3. "Proposal on requesting the company's general meeting of shareholders to authorize the board of directors
and its authorized person to handle matters related to the issuance of corporate bonds"
According to the company's current corporate bond issuance and listing Arrangements, in order to complete the relevant work of this corporate bond legally, efficiently and orderly, in accordance with the "the People's Republic of China Company Law", "the People's Republic of China Securities Law", "Corporate Bond Issuance Pilot Measures" and other laws and regulations and the relevant provisions of the "Articles of Association of Zhejiang Jianfeng Group Co., Ltd.", the company's board of directors intends to request the company's general meeting of shareholders to authorize the board of directors to handle All matters related to the issuance of corporate bonds, the specific content includes but is not limited to:
1, within the scope permitted by laws and regulations, according to the specific conditions of the company and the market, formulate the specific issuance plan of this issue of corporate bonds and revise and adjust the issuance terms of this issue of corporate bonds, including but not limited to the specific issuance scale, bond term, bond interest rate and determination method, issuance timing, whether to issue in installments and the number of issues and the issuance scale of each issue, online and offline issuance ratio, whether to design the resale clause and redemption clause, whether to provide guarantee and guarantee method, the time limit and method of repayment of principal and interest, whether to allocate to shareholders and the specific arrangement of placing to shareholders, listing place and decision to raise funds the specific use of all matters relating to the issuance of the Company's bonds;
2, decide and hire intermediaries to participate in this corporate bond issuance;
3, select bond trustee, sign "bond trustee management agreement" and formulate "bondholder meeting rules";
4, handle the declaration of this corporate bond issuance, and after the completion of this issuance, to handle the listing of the bonds issued, including but not limited to formulation, approval, authorization, signing, execution, modification and completion of all necessary documents related to the issuance and listing of corporate bonds, contract / agreement, contract ( includes but not limited to prospectus, sponsorship agreement, underwriting agreement, bond trusteeship agreement, listing agreement, various announcements and other legal documents ) and appropriate information disclosure in accordance with laws, regulations and other regulatory documents;
5, request the general meeting of shareholders to authorize the board of directors to decide the amount of funds raised to repay company debt and supplement working capital according to the company's financial situation.
6. If the regulatory authority's policy on the issuance of corporate bonds changes or market conditions change, except for matters involving relevant laws, regulations and the company's articles of association that must be re-voted by the general meeting of shareholders, Authorize the board of directors to make corresponding adjustments to the specific corporate bond issuance plan and other related matters based on the new policies and opinions of the regulatory authority or new market conditions;
7. When the market environment or policies and regulations undergo major changes, the board of directors is authorized to decide whether to continue the corporate bond issuance based on the actual situation.
8, handle all other necessary matters related to the issuance of corporate bonds and listing.
. This authorization shall be from the date of deliberation and approval by the general meeting of shareholders to the date of completion of the above authorization.
The board of directors of the company intends to authorize the chairman and the secretary of the board of directors to handle specific matters related to this issuance in accordance with the scope of authorization of the general meeting of shareholders.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
This proposal still needs to be reviewed and approved by the company's shareholders' meeting.
4. "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors to Take Repayment Safeguard Measures in Case of Expected Failure to Pay Bond Principal and Interest on Time or Failure to Pay Bond Principal and Interest on Time"
The Company Requested the General Meeting of Shareholders to Authorize the Board of Directors to Make the following Resolutions and Take Corresponding Measures :
1 , no distribution of profits to shareholders;
2 , suspending the implementation of capital expenditure projects such as major foreign investment, mergers and acquisitions;
3 , reduce or suspend the salaries and bonuses of directors and senior management personnel;
4 , the main responsible person shall not be transferred.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
This proposal still needs to be reviewed and approved by the company's shareholders' meeting.
Proposal of 5. on Convening the First Extraordinary General Meeting of Shareholders in 2013
Decided to Convene the First Extraordinary General Meeting of Shareholders in 2013 on 1 March 22 (Tuesday) in 2013 , for details, please refer to the "Notice on Convening the First Extraordinary General Meeting of Shareholders in 2013 " published on the same day.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
December 31, 2012
More information
Two Cement Enterprises Prosperous Production and Sales in May
With the gradual easing of the new crown epidemic, all over the project has started, Hubei, Yunnan two provinces cement market continued to improve, Daye peak cement company, Yunnan peak cement company two enterprises have recently shown a good momentum of production and sales. In May, the sales volume of Yunnan Jianfeng cement continued to rise. As of the time of publication, the average daily shipment volume reached more than 7400 tons, and the highest daily shipment volume reached more than 8700 tons, and the production capacity was fully released. Over the past few days, Yunnan Peak Packaging System has made great efforts to overcome the impact of narrow distribution sites and many cement varieties to ensure the completion of delivery tasks with good quality and quantity every day. In order to further balance production and sales and create conditions for the homogenization of cement delivered from the factory, Yunnan peak packaging system puts forward work requirements for relevant posts, emphasizes equipment inspection and process inspection during production, strictly implements safety operation procedures, and maintains safe and efficient operation of the system. Due to the impact of the new crown epidemic, Hubei cement market started late, Wuhan market is the hardest hit area, the current project construction is still not fully started, the volume pressure is greater. For this reason, daye peak departments cooperate closely, increase market development efforts, develop new mixing stations, focus on increasing the bulk share of Xianning, Huanggang and Wuhan markets, seize the opportunity of fine weather, and achieve the goal of rapid output. Internally, on the basis of equipment technical renovation and production capacity improvement, the delivery is effectively guaranteed, and the daily delivery capacity can basically be maintained at 10,000 tons. In May, Daye Peak sold more than 300000 tons of cement, an increase of 20% over the same period last year, with an average daily sales volume of more than 9900 tons, the highest in the current period since Daye Peak was put into production.
2020
07-31
The company's "safe production month" activities are about to start
June 2020 is the 19th national "safe production month", the theme of the activity is "eliminating hidden dangers of accidents and building a strong line of defense". A few days ago, the group company issued a notice to arrange the activities related to the organization of "safe production month" and put forward requirements. According to the group's "safe production month" activity plan, different key thematic activities will be held in the four weeks of June. The first week is the "Publicity and Safety Education Week", which focuses on the use of WeChat groups, electronic screens, publicity boards, banners, slogans and other forms for safety publicity, and organizes the study of national safety regulations, company safety system specifications and accident-free factory creation standards, Organize to watch safety warning education films, learn accident cases, etc., and improve employees' safety awareness by creating a safety atmosphere and organizing learning activities. The focus of the activities in the second week is "looking for potential sources of danger around you". Each unit takes departments and teams as units to investigate and analyze the potential risk factors in the process of daily production, maintenance and operation, find out the hazard sources that have not been included in the scope of risk point control, and report to the safety management department of the unit to form a risk assessment report, put forward solutions or suggestions, and supervise the implementation of rectification and timely eliminate potential safety hazards. The third week is the "on-site safety innovation achievements exhibition week", which focuses on the achievements of each unit in on-site safety management and on-site safety facilities in the past year, which are displayed in the form of pictures and texts through beautiful articles and wechat, so as to learn from each other and promote common progress. The fourth week is the "safety training and drill week", and the group company organizes the standardization of safety production and the elimination of hidden dangers.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-30
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-22
On April 24, Jiang Xiaomeng, chairman of the group company, presided over the 14th meeting of the 10th board of directors of the company, and deliberated and passed 14 related reports and motions such as the 2019 annual board of directors report, the 2019 general manager business report and the 2019 annual report. The general manager's report pointed out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023) and the new three-year business plan (2019-2021) for each business sector. the management team has carried out various operation and management work in an orderly manner around the general policy of "innovation and reform, integration and promotion, scientific layout and steady development", and has better completed the business objectives set by the board of directors at the beginning of the year. In the whole year, the company achieved a total operating income of 3.548 billion billion yuan, an increase of 5.51 percent over the same period last year; net profit attributable to shareholders was 0.725 billion billion yuan, with earnings per share reaching 2.11 billion yuan, an increase of 23.14 percent over the same period last year, a record high; total assets at the end of the year were 5.475 billion billion yuan, an increase of 11.71 percent over the same period last year; and net assets attributable to shareholders were 3.789 billion billion yuan, an increase of 19.81 percent. During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, the overall operation of the cement industry in 2019 is stable, and the industry benefits are further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons of clinker.
2020
07-31